[NonUS -- Symbol : Private]
Av. Bento Gonclaves, 9500, campus UFRGS-Predio
43431, Porto Alegre-RS, Brazil
email: fkreutz@fkbiotec.com.br
Website: http://www.fkbiotec.com.br
phone: 55-51-3352-6864
Industry Classification: Pharmaceuticals and Healthcare-->Medical Devices and Diagnostics--
>Diagnostic Devices and Imaging
Business Summary :
FK-Biotecnologia S.A. is a biotech company created on 1999. It was incorporated on 2000. It's focus on
research and development, production and distribution of immunodiagnostics kits. The company was initially
incubated at Incubadora Tecnologica CIENTEC foundation subordinated to the Science and Technology
Secretary of the Rio Grande do Sul State. FK-Biotecnologia is a new concept on Science, Technology and
Business in Brazil. FK-Biotecnologia technology and Know how involve areas such as monoclonal
antibody production, assay development, bi-specific antibodies, biosensors and point of care testing. The
company has a profound knowledge of the Brazilian diagnostics field, is able to absorbed technology fast,
maintaining international standards of quality. Its most important technological development has been in the
field of vaccines for cancer. The company is currently developing an experimental vaccine composed of
cancer cells that work as medical treatment as they are capable of stimulating the immunological system to
fight against cancer. The company act on market opportunities were technology can aggregate the highest
value possible. The company received its operation authorization from the Health Ministry (ANVISA) on May
2001 and became one few industries authorized and qualified to produce immunodiagnostics kits in Brazil.
FK-Biotecnologia established a distribution network covering the most important regions of Brazil (Rio
Grande do Sul, Santa Catarina, Sao Paulo, Rio de Janeiro and Minas Gerais. The other regions can also be
supply by direct marketing and using a very effective e-commerce system specializes on laboratory
supplies. Porto Alegre is located on a strategic place to reach all Mercosul countries, expanding the
distribution range to those areas of South America. The company represents an important reference for the
Brazilin technology industry, as it became the first biotech company in Brazil to receive venture capital. This
investment was performed by the RSTec fund administrated by the Compania Riograndense de
Partiucipacoes (CRP). This fund was created with investments from the BNDESPar, SEBRAE, BID-FOMIM.
